Upload
grace-welch
View
215
Download
1
Tags:
Embed Size (px)
Citation preview
MODELS OF SYSTEMIC MODELS OF SYSTEMIC TREATMENT IN BREAST CANCERTREATMENT IN BREAST CANCER
EMRA against cancer 1EMRA against cancer 1stst Forum Forum
““NGOs and cancer: Challenges and opportunitiesNGOs and cancer: Challenges and opportunities””
Marrakech, 18 - 19 June 2010Marrakech, 18 - 19 June 2010
IntroductionIntroduction• Breast cancer: most common malignancy in Breast cancer: most common malignancy in
women .women .
• Advances Advances in clinical and translationnel in clinical and translationnel researchresearch..
• Systemic treatment: chemotherapy, targeted Systemic treatment: chemotherapy, targeted therapy, endocrine therapytherapy, endocrine therapy
Survival improvementSurvival improvement
Peto Meta analysisPeto Meta analysis
Peto et al, SABCS 2007
INO Recruitement: 1985 - 2006 INO Recruitement: 1985 - 2006
0
200
400
600
800
1000
1200
Sein Col Poumon Colo-rectum Cavum
Breast cancer treatmentBreast cancer treatment
Loco-regional:Loco-regional:
SurgerySurgery
RadiotherapyRadiotherapy
Systemic:Systemic:ChemotherapyChemotherapyEndocrine therapyEndocrine therapyTargeted therapyTargeted therapy
Personalize Medicine: Personalize Medicine: Right Drug to the Right PatientRight Drug to the Right Patient
Lum A Lum B Basal Her2
claudin low
Chan ging PortraitsConcept evolutionConcept evolution
Biology as the Framework for Biology as the Framework for ProgressProgress
Pathology
Clinical Characteristics
Biology
Treatment improvementTreatment improvement
Indications of systemic Indications of systemic treatmenttreatment
Adjuvant setting
Primary systemic therapy
Palliative chemotherapy
ADJUVANT SETTINGADJUVANT SETTING
Adjuvant chemotherapyAdjuvant chemotherapyGoalsGoals
Post operative Post operative
Against micrometastasic spread Against micrometastasic spread
Aim : Improve survivalAim : Improve survival
Adjuvant chemotherapy:Adjuvant chemotherapy:
Active drugsActive drugs
• Methotrexate Methotrexate • 5 FU5 FU• CyclophosphamideCyclophosphamide• AnthracyclinesAnthracyclines• Taxanes (paclitaxel, docetaxel)Taxanes (paclitaxel, docetaxel)
Adjuvant chemotherapy:Adjuvant chemotherapy:
RegimensRegimens
6 FAC 6 FAC 6 FEC 6 FEC 4 AC 60 4 AC 60 4 TC4 TC3 FEC+ 3 Docetaxel 3 FEC+ 3 Docetaxel 4AC 60 + 12 Paclitaxel4AC 60 + 12 Paclitaxel
Adjuvant Treatment and Survival Adjuvant Treatment and Survival Improvement Over Past 40 YearsImprovement Over Past 40 Years
Peto et al, SABCS 2007
Taxanes > anthra > CMF > No chemotherapy
10
0 5 10 0 5 10 0 5 10
50
0
40
30
20
Breast cancer mortality
Anthr.31.0%
Taxane25.9%
%+ SE
10-y gain 5.1% (SE 1.6)Lorank 2p < 0.00001
15.3
12.8
Years
10-y gain 4.3% (SE 1.0)Lorank 2p < 0.00003
10-y gain 4.3% (SE 1.0)Lorank 2p < 0.00001
YearsYears
CMF31.3%
Anthr.27.0%
Control36.4%
CMF32.2%
20.5
17.8
19.9
16.5
Peto metanalysis EBCTCG up date 2007
Role of taxanes:Role of taxanes:Docetaxel Meta-analysis: TrialsDocetaxel Meta-analysis: Trials
StudyStudy NodesNodes No. PtsNo. Pts RegimenRegimen F/U (yr)F/U (yr)
GEICAM 9805GEICAM 9805 N0N0 10601060 TAC vs FACTAC vs FAC 55
ECOG 2197ECOG 2197 N0/ N+ ≤3N0/ N+ ≤3 1893/9891893/989 AT vs ACAT vs AC 5 5
USO 9735USO 9735 N0/N+N0/N+ 487/529487/529 TC vs ACTC vs AC 7 7
UK TACTUK TACT N0/N+N0/N+ 835/3327835/3327 FEC-T vs FEC/E-CMFFEC-T vs FEC/E-CMF 55
RAPP-01RAPP-01 N0/N+ ≤3N0/N+ ≤3 627627 AT vs ACAT vs AC 55
FinHerFinHer N+ (89%)N+ (89%) 10101010 T-FEC vs V-FECT-FEC vs V-FEC 55
BCIRG001BCIRG001 N+N+ 14911491 TAC vs FACTAC vs FAC 4.54.5
TAXIT 216TAXIT 216 N+N+ 972972 E-T-CMF vs E-CMFE-T-CMF vs E-CMF 55
PACS01PACS01 N+N+ 19991999 FEC-T vs FECFEC-T vs FEC 55
BIG2-98, TAX315BIG2-98, TAX315 N+N+ 28872887 A-T (AT)-CMF vs A(C)-CMFA-T (AT)-CMF vs A(C)-CMF 55
WSG/AGOWSG/AGO N+ ≤3N+ ≤3 18371837 EC-T vs FECEC-T vs FEC 55
HORG HORG N+N+ 756756 T-EC vs FECT-EC vs FEC 55
20,698 Patients Laporte S, et al. SABCS 2009..
Docetaxel Meta-Analysis: DFS and OS Docetaxel Meta-Analysis: DFS and OS According to Nodal StatusAccording to Nodal Status
• Overall, the pooled HR estimate [95% CI] for DFS was 0.82 [0.75;0.89] (P<0.001) in favor of docetaxel-based chemotherapy
• The overall estimated HR for OS was 0.82 [0.74;0.91] (P<0.001)
Laporte S, et al. SABCS 2009.
Worldwide Overview: Chemotherapy vs no Worldwide Overview: Chemotherapy vs no chemotherapy, by age &ER, ratio of recurrence chemotherapy, by age &ER, ratio of recurrence
rates in years 0-4rates in years 0-4
AgeAge ER-poorER-poor ER+ER+
<50<50 0.57 (0.07)0.57 (0.07) 0.51 (0.06)0.51 (0.06)
50-5950-59 0.65 (0.07)0.65 (0.07) 0.75 (0.05)0.75 (0.05)
60-6960-69 0.78 ( 0.08)0.78 ( 0.08) 0.81 (0.05)0.81 (0.05)
Peto et al, SABCS 2007
In summaryIn summary
• Adjuvant chemotherapy:Adjuvant chemotherapy: Survival benefit in node Survival benefit in node positive and negative breast cancerpositive and negative breast cancer
• Anthracyclines based regimen.Anthracyclines based regimen.
• Anthracyclines + TaxanesAnthracyclines + Taxanes• Node positifNode positif• High risk node negatif (SBRIII, RH-, LVI, Her3+..)High risk node negatif (SBRIII, RH-, LVI, Her3+..)
Targeted therapyTargeted therapy
Trastuzumab.Trastuzumab.
HER2 over expressing tumor.HER2 over expressing tumor.
Duration : 1 year.Duration : 1 year.
Trastuzumab trialsTrastuzumab trials
Cancerous cell
RH
H
Adrenal glandbreast
Fat
TAMOXIFEN
CASTRATION
Aromatase inhibitors
FULVESTRANT
Ovary
Hypophyse
LHRH
Hypothalamus
FSH LH
Antagonist
Rôle des sécrétions hormonales dans la prolifération tumorale et site d’action des Tt anti hormonauxEndocrine therapy
Endocrine therapy: in summaryEndocrine therapy: in summary
RH: positive (≥1%)RH: positive (≥1%)
Premenopausal women : TamoxifenPremenopausal women : Tamoxifen
Post menopausal women: Aromatase Post menopausal women: Aromatase inhibitorsinhibitors
5 years 5 years
IndicationsIndications
Prognostic factorsPrognostic factors
Predictive factorsPredictive factors
TNM
First «First « generation » factorsgeneration » factorsAgeAgeGrade Grade Histological typeHistological typeRE/RP, HER2RE/RP, HER2Vascular invasionVascular invasion
« 2d generation » factors« 2d generation » factors
•Proliferation indexProliferation index• UPA, PAI-1UPA, PAI-1• MicrometastasisMicrometastasis•Alpha II Topoisomerase Alpha II Topoisomerase
« 3d generation » factors:« 3d generation » factors:
Multigenic signatures:Multigenic signatures:Oncotype DxOncotype DxMammaprintMammaprintGenomic gradeGenomic grade
Indications: adjuvant chemotherapyIndications: adjuvant chemotherapy
Anthracycline regimens: all patients
Anthracyclines + TaxanesAnthracyclines + Taxaneso Node positifNode positifo High risk node negatif (SBRIII, RH-, LVI, Her3+..)High risk node negatif (SBRIII, RH-, LVI, Her3+..)
o
Trastuzumab: Her 2 neu +++:
HR +: endocrine therapy (pre vs post-menopausal)
Indications : Consensus conferencesIndications : Consensus conferences• NCCN 2010NCCN 2010
• St Gallen 2009St Gallen 2009
• St Paul de vence St Paul de vence
Goldhirsch, Ann Oncol 2009
Primary systemic TherapyPrimary systemic Therapy
Primary systemic Therapy:Primary systemic Therapy:GoalsGoals
• Induction therapy, preoperative systemic therapy, neo-adjuvant Induction therapy, preoperative systemic therapy, neo-adjuvant chemotherapy.chemotherapy.
• Down staging Down staging
• Breast-conservative surgeryBreast-conservative surgery
• Treat early micro metastasesTreat early micro metastases
• Study of predictive factorsStudy of predictive factors
• Assess chemo sensitivityAssess chemo sensitivity
Primary systemic therapy: anthracyclines NSABP B-18 , N: 1,523
Wolmark NSABP B18 , JNCI 2001
NSABP B18 update ( 2007)
Tumor response Nodal response
Overall Survival Disease Free Survival
NSABP B18 update ( 2007)
DFS and pCR
OS and pCR
Wolmark, NCI Meeting March 2007
OS and PFS benefit correlated to pCR
Taxanes: neo-adjuvant settingTaxanes: neo-adjuvant setting
• Slide Aberdeen trial Slide Aberdeen trial
Aberdeen, TAX 301
% pCR
0 10 20 30 40
CVAP x 8
CVAP x 4 - - >
Doc x 4 3434
1616
Aberdeen, TAX 301
Taxanes: neo-adjuvant settingTaxanes: neo-adjuvant settingPathologic Complete Responses
% L
iber
e da
Mal
attia
Tempo (settimane)
Risposta iniziale Randomizzate a Docetaxel
Nessuna Risposta iniziale Trattate tutte con Docetaxel
Follow Up medio: 104 Settimane( Range 13 - 187)
Risposta iniziale Randomizzate a CVAP
p=0.022
time (months)6050403020100
Surv
ival pro
babili
ty
1.0
.9
.8
.7
docetaxel
CVAP
p=0.05
Log Rank Test
Disease Free SurvivalDisease Free Survival Overall SurvivalOverall Survival
Docetaxel DFS and OSSmith, JCO 2002
Hutcheon, 3rd EBCC 2002
Taxanes: neo-adjuvant settingTaxanes: neo-adjuvant settingPathologic Complete Responses
SCHEDULESSCHEDULES
• Sequentiel anthracyclines and Taxanes.Sequentiel anthracyclines and Taxanes.
• Increase rate of pCR / successful breast conservation Increase rate of pCR / successful breast conservation surgery / node negative patients by 50%.surgery / node negative patients by 50%.
• Trastuzumab is indicated for Trastuzumab is indicated for Her 2-neu +++ Her 2-neu +++ patients, to patients, to be continued in adjuvant settingbe continued in adjuvant setting . .
For whom?For whom?
• Inoperable breast cancer:Inoperable breast cancer:
o Inflammatory breast cancer. Inflammatory breast cancer. o Locally advanced breast cancer (T4Nx, TxN2-3)Locally advanced breast cancer (T4Nx, TxN2-3)
• Operable breast cancer:Operable breast cancer:
o Conservative surgeryConservative surgery
METASTATIC SETTINGMETASTATIC SETTING
METASTATIC SETTINGMETASTATIC SETTING
• Goals of therapy in MBC:Goals of therapy in MBC:
– Improve survivalImprove survival
– Delay time to disease progressionDelay time to disease progression
– Palliate symptomsPalliate symptoms
SCHEDULESSCHEDULES
Monochemotherapy :Monochemotherapy :
Doxorubicin Doxorubicin Epirubicin Epirubicin Liposomal DoxorubicinLiposomal DoxorubicinPaclitaxel Paclitaxel Docetaxel Docetaxel Gemcitabine Gemcitabine Vinorelbine Vinorelbine Capecitabine Capecitabine Cisplatine Cisplatine CarboplatinCarboplatin
• Targeted therapyTargeted therapy
•TrastuzumabTrastuzumab
•LapatinibLapatinib
•BevacizumabBevacizumab
Monochemotherapy:
Fumoleau IGR 2006
Targeted therapy
SCHEDULESSCHEDULES• Polychemotherapy (Her2 neu -):Polychemotherapy (Her2 neu -):
• FAC FAC • FEC FEC • AC 60 AC 60 • ATAT• APAP• Docetaxel + capécitabine Docetaxel + capécitabine • Paclitaxel + gemcitabine Paclitaxel + gemcitabine • Docetaxel + gemcitabine Docetaxel + gemcitabine • Capecitabine + Vinorelbine Capecitabine + Vinorelbine • Capecitabine + Vinorelbine Capecitabine + Vinorelbine • Ixabepilone + Capécitabine Ixabepilone + Capécitabine • Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel • Etoposide + Cisplatine Etoposide + Cisplatine • Gemcitabine + Cisplatine Gemcitabine + Cisplatine • Gemcitabine + Oxaliplatine Gemcitabine + Oxaliplatine • Paclitaxel + CarboplatinePaclitaxel + Carboplatine
Fossati JCO 1998
Polychemotherapy versus monochemotherapy: Meta-analysis
Polychemotherapy = sequentiel monochemotherapy
ECOG 1193, Sledge 2003
SCHEDULES in Her2 neu positive diseaseSCHEDULES in Her2 neu positive disease
Trastuzumab + Docetaxel Trastuzumab + Docetaxel Trastuzumab + Paclitaxel Trastuzumab + Paclitaxel Trastuzumab + VinorelbineTrastuzumab + VinorelbineTrastuzumab + Capécitabine Trastuzumab + Capécitabine Lapatinib + CapécitabineLapatinib + Capécitabine
Trastuzumab in Her2 neu positive diseaseTrastuzumab in Her2 neu positive diseaseprognosisprognosis
Trastuzumab in Her2 positive disease = Her 2-Trastuzumab in Her2 positive disease = Her 2-
Endocrine therapyEndocrine therapy Premenopausel women:Premenopausel women:
Tamoxifene + castration Tamoxifene + castration Adjuvant Tamoxifene : no standard, recommendation : ovarien Adjuvant Tamoxifene : no standard, recommendation : ovarien
ablation± AIablation± AI
Menopausel women: Menopausel women: Not pretreated by AI:Not pretreated by AI:
Standard : 3d generation AI (anastrozole, létrozole)Standard : 3d generation AI (anastrozole, létrozole) Exemestane Exemestane Option : fulvestrant Option : fulvestrant
Pretreated by non stéroïdiens AIPretreated by non stéroïdiens AI No standardNo standard Option : Fulvestrant, Exemestane, TamoxifeneOption : Fulvestrant, Exemestane, Tamoxifene
INDICATIONSINDICATIONS
According to :According to :
Hormonal statusHormonal status
Her2 statusHer2 status
Disease agressiveness: Disease agressiveness:
Agressive diseaseAgressive disease : symptomatic disease, multiple metastatic : symptomatic disease, multiple metastatic sites, visceral metastases, high tumor burden, relapse interval< sites, visceral metastases, high tumor burden, relapse interval< 2years2years
Non agressiveNon agressive disease : asymptomatic, relapse interval > disease : asymptomatic, relapse interval > 2years (5years ?), low tumor burden, few metastatic sites, slow 2years (5years ?), low tumor burden, few metastatic sites, slow evolutive diseaseevolutive disease
Prognostic factors Favorable Unfavorable
PS Good poor
Sites of disease Bone, soft, tissue Viscera
N°sites disease Oligo Multiple
HR status Positive Negative
Her-2/Neu Negative Positive
Disease free interval >2 years < 2 years
Prior adjuvant therapy NO Yes
Prior therapy MBC NO YES
Beslija, Ann oncol 2007
Treatment criteria choice
In summaryIn summary
Her2+Her2+ Her2-Her2-
Agressive Agressive Non agressiveNon agressive AgressiveAgressive Non Non agressiveagressive
RH+RH+ TrastuzumabTrastuzumab+ CT+ CT
Trastuzumab + Trastuzumab + HormonoHormono PolyCTPolyCT HormonoHormono
RH-RH-TrastuzumabTrastuzumab
+ CT+ CT TrastuzumabTrastuzumab +/- CT+/- CT
PolyCTPolyCT Sequentiel Sequentiel MonoCTMonoCT, , PolyCTPolyCT??
Conclusion
Many therapeutic options real survival improvement
Area of targeted therapy and molecular profiling: right drug to the right patient
Morrocco: recommendations in accordance with literature
Morrocan chemotherapy guide
Chimiothérapie adjuvante (60% des patients):
Pour les patientes Her 2-neu - :3cycles de FEC (Epirubicine 100mg/m2, 5 Fluorouracile 500mg/m2,
cyclophosphamide 500mg/m2) + 3 cycles de docétaxel 100mg/m2
Pour les patientes Her 2-neu + (20% des cas): 3cycles de FEC (Epirubicine 100mg/m2, 5 Fluorouracile 500mg/m2,
cyclophosphamide 500mg/m2) + 3 cycles de docétaxel 100mg/m2+ Trastuzumab 8mg/Kg puis 6mg/Kg (tous les 21 jours), pendant une année
Chimiothérapie de première ligne métastatique (40% des patients):
Moyens multiples: chimiothérapie, hormonothérapie, thérapeutiques cibléesMonochimiothérapie versus polychimiothérapie ?Indication dépend de plusieurs facteurs :
Age, co-morbidités (OMS), vécu et préférence du patientNiveau d’agressivité de la tumeur : volume tumoral, nombre de sites
métastatiques, présence d’envahissement viscéral, cinétique tumorale, intervalle libre de rechute.
Profil biologique de la tumeur : RH et Her 2 +++Expositions aux thérapeutiques antérieures (adjuvant ou néo-adjuvant)
Difficile d’élaborer un seul protocole
Chimiothérapie de première ligne métastatique (40% des patients):
On distingue les patientes HER 2 +++ (20% des patientes):
Patientes ayant déjà reçu taxanes : Trastuzumab 8mg/Kg puis 6mg/Kg (tous les 21 jours) + vinorelbine 25mg/m2 j1j8 (tous les 21 jours)
Patientes n'ayant pas reçu de taxanes: Trastuzumab 8mg/Kg puis 6mg/Kg + docetaxel 100mg/m2 J1 (tous les 21 jours)
Chimiothérapie de première ligne métastatique (40% des patients):Pour les patientes Her2-:
Patientes n’ayant reçu ni taxanes ni anthracyclines:
Si Monochimiothérapie : Doxorubicine, Docetaxel Si polychimiothérapie :
AT : Doxorubicine + DocetaxelOu séquentiel programmé : 4 FEC + 4 Docetaxel
Patientes n'ayant pas reçu de taxanes (pré-traitées par anthracyclines) :Si Monochimiothérapie : Docetaxel Si polychimiothérapie : Docetaxel + capécitabine
Patientes ayant déjà reçu anthracyclines et taxanes: Si Monochimiothérapie : Vinorelbine ou Capécitabine Si polychimiothérapie : Capécitabine + Vinorelbine